HomeHealthAlzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic

Alzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic

NEWYou can now listen to Fox News articles!

A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology.

The study looked at levels of phosphorylated tau 217 (p-tau217) in 2,178 cognitively unimpaired adults, ranging in age from 60 to 90. It also considered age, gender and whether participants carried the APOE ε4 genetic variant, which is associated with Alzheimer’s risk.

The participants, drawn from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative, underwent blood biomarker testing, genetic testing and multiple cognitive assessments.

ALZHEIMER’S WARNING SIGNS COULD EMERGE YEARS BEFORE MEMORY LOSS, STUDY FINDS

While APOE ε4 had a modest association with risk after accounting for p-tau217, older age was associated with greater risk, according to the researchers.

For example, at the same elevated p-tau217 level, a 65-year-old faced a 6% estimated five-year risk of mild cognitive impairment, compared to a 37% risk for an 85-year-old.

A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years. (iStock)

Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain, senior author Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist, noted. 

“The test tells you, just by taking a blood sample, whether someone has that pathology in the brain,” he told Fox News Digital, adding higher levels of the pathology are associated with a greater risk of progressing from normal cognition to impairment.

10 HEALTH CONDITIONS MAY BE LINKED TO ALZHEIMER’S YEARS BEFORE DIAGNOSIS

Detecting p-tau217 in blood may be “less invasive and potentially more scalable” than using PET scans to measure amyloid burden, a hallmark of Alzheimer’s disease that is associated with future cognitive impairment.

“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, said in a news release.

Amyloid beta

Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain. (iStock)

If investigational treatments are found to be effective at preventing or delaying cognitive decline, this blood test could take on greater significance, according to the researchers.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” Jack noted.

Study limitations

The risk estimates were developed in the Mayo Clinic Study of Aging, which is drawn from a specific geographical area.

“The older population in southeast Minnesota is not representative of the entire United States,” Jack said.

CLICK HERE FOR MORE HEALTH STORIES

While the study’s methods could be applied to other populations, the researcher said the findings need to be replicated outside the region.

scientist analyzing blood test tubes

The study does not establish that routine blood testing prevents dementia or improves clinical outcomes. (iStock)

The risk prediction model is not yet ready for routine screening of people without cognitive symptoms, according to the research team.

“There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain,” Jack told Fox News Digital. “Therefore, there’s no reason to do the test. … The results of the test would not change your medical management at all since there’s no treatment available.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

That could change if preventive treatments are approved, he added.

The study does not establish that routine blood testing prevents dementia or improves clinical outcomes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Many elderly people who have the pathology in the brain at lower levels will never develop symptoms in their lifetime,” Jack added, noting that some people with Alzheimer’s-related pathology may also die of another cause before developing cognitive impairment.

Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments